Amgen (AMGN) 10-K2022 FY Annual report

Filed: 9 Feb 23, 4:26pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abruptly, adjunctive, alpha, antagonist, apprenticeship, argued, arisen, arm, armed, ASAN, ASCVD, ASR, avacopan, Bergamo, biomarker, Bristol, burdensome, Carnation, check, checkpoint, ChemoCentryx, coaching, commerce, commodity, conflict, contravention, controversy, crossover, customary, cytoplasmic, DAHLIA, de, Derek, divested, divestiture, documentary, double, doublet, drake, drawn, Dublin, Dusseldorf, EIS, embed, eosinophilic, epidemiology, erenumab, ethnic, evolution, exfiltrated, experimentation, exploratory, export, facto, fibroblast, Finansal, Fiona, FOURIER, Gensenta, GIPR, Goldman, green, HMA, hoc, Homyk, Hong, hundred, hybrid, impede, inflammatory, inhibitory, inquiry, interference, interleukin, invited, IRA, jeopardize, Kong, la, listening, macroeconomic, mentoring, MI, michael, Miller, Mizuho, monotherapy, Napoli, nondeductible, nonpersonal, nonstrategic, obesity, Okta, OLE, opt, outpace, pancreatic, PDAB, perimeter, pharmacologic, phishing, photovoltaic, Pillartree, pleading, policymaking, polypeptide, posttrial, prostate, pursuit, rare, recede, reconnaissance, reinforce, reinsurance, reintroduced, relinquished, reside, RIVER, rocatinlimab, romosozumab, Sanayi, SAS, Schall, session, Society, sooner, strict, subcutaneously, switching, Teribone, Ticaret, tolerability, tool, Ukraine, unchanged, unilaterally, upcoming, upper, Utah, ve, voluntarily, withholding, workspace

Removed: ACA, administratively, administrator, affiliate, aim, Alder, answered, assembled, Baltimore, Bayer, behavior, bill, Blue, breached, Brexit, budget, capped, ceiling, Celanese, Chapter, Cleveland, clinic, commence, congressional, contingency, counterclaim, cured, daratumumab, DaVita, debtholder, deferral, Dell, demographic, designation, detriment, enjoining, entering, entrant, epidermal, eptinezumab, exit, focusing, Fraternal, HMO, Hospira, House, Immunex, Indemnity, inducement, instituting, inter, intervention, IPR, IRP, Johnston, Kabi, largely, leveraging, locally, Lodge, Lori, Louisiana, mainland, matured, Mayor, Miami, migration, minimizing, misrepresentation, MN, Momenta, monopolized, moving, mutation, NaN, nearest, negligent, noninfringement, notwithstanding, Nuevolution, Onyx, outpatient, package, panitumumab, Paul, payor, pegfilgrastim, penalty, Pipe, Police, proceeding, progressive, PROMESA, PTAB, purported, reallocated, release, repaid, repeal, replacement, requesting, Roche, rounding, Samsung, satisfying, Senate, sheet, Shield, situation, Sourcing, sponte, St, stable, staying, stressed, structural, sua, superseded, sustain, taxed, territorial, tezepelumab, therapeutically, thicket, Title, unenforceable, Union, unpatentable, unresectable

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated AMGN transcripts

AMGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:

(i)the accompanying Annual Report on Form 10-K of the Company for the period ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii)information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


February 9, 2023			/s/ ROBERT A. BRADWAY
			Robert A. Bradway
			Chairman of the Board,
			Chief Executive Officer and President

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Certification of Chief Financial Officer

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:

(ii)information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


February 9, 2023			/s/ PETER H. GRIFFITH
			Peter H. Griffith
			Executive Vice President and Chief Financial Officer